Reuters
U.S. doctors reconsider Pfizer’s Paxlovid for lower-risk COVID patients
Use of Pfizer Inc’s COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time. More quarantine time “is not a crowd-pleaser,” Dr. Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. Use of Pfizer’s Paxlovid, authorized to treat newly infected, at-risk people in order to prevent severe illness, has soared as infections have risen.
Source: finance.yahoo.com
Related posts:
VMware Stockholders Will Get a Windfall in Broadcom Merger
3 Dividend Stocks That Are Screaming Buys in November
World ‘plunging towards societal collapse’ as era of cheap money ends
Do we really need $1M in retirement savings? Not even close, one top economist says
Electric cars will never dominate market, says Toyota